From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: SMWH

Search articles by EPIC code
EPIC SMWH
views

When was the last time you went to a WH Smith store?

I will have a listen later to the quarterly call from GlaxoSmithKline (GSK) following its first quarter numbers today. The numbers were fine and specifically mentioned the good performance of its pharmaceutical business ahead of the proposed demerger in July. I wrote about all this a couple of months ago and my advice remains to stay a holder here and make a call whether to retain one or both on the demerger in a few months time. If only all investments were as straightforward as the last 15 months in GlaxoSmithKline. And talking about more complex investments brings us to WH Smith (SMWH)...

Page 1 of 5 (42 articles)
Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments